$6.43
+0.1
(+1.58%)▲
Revenue is down for the last 2 quarters, 50.35M → 42.46M (in $), with an average decrease of 15.7% per quarter
Netprofit is down for the last 2 quarters, 88.55M → -3.48M (in $), with an average decrease of 103.9% per quarter
2.02%
Downside
Day's Volatility :3.89%
Upside
1.91%
67.81%
Downside
52 Weeks Volatility :74.16%
Upside
19.73%
Period | Assertio Holdings, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.03% | 0.7% | -6.8% |
6 Months | 111.0% | -8.3% | -6.0% |
1 Year | 104.85% | -1.9% | -4.6% |
3 Years | 58.25% | 25.3% | 25.9% |
Market Capitalization | 359.6M |
Book Value | $4.5 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 1.75 |
PE Ratio | 3.69 |
PEG Ratio | 0.62 |
Wall Street Target Price | 9.75 |
Profit Margin | 59.86% |
Operating Margin TTM | 35.37% |
Return On Assets TTM | 9.52% |
Return On Equity TTM | 53.56% |
Revenue TTM | 162.2M |
Revenue Per Share TTM | 3.35 |
Quarterly Revenue Growth YOY | 16.2% |
Gross Profit TTM | 138.3M |
EBITDA | 88.5M |
Diluted Eps TTM | 1.75 |
Quarterly Earnings Growth YOY | 12.11 |
EPS Estimate Current Year | 0.37 |
EPS Estimate Next Year | 0.61 |
EPS Estimate Current Quarter | 0.13 |
EPS Estimate Next Quarter | 0.14 |
What analysts predicted
Upside of 51.63%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 380.7M | ↓ 16.49% |
Net Income | -102.5M | ↑ 15.53% |
Net Profit Margin | -26.92% | ↓ 7.46% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 311.8M | ↓ 18.11% |
Net Income | 36.9M | ↓ 136.01% |
Net Profit Margin | 11.84% | ↑ 38.76% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 229.5M | ↓ 26.39% |
Net Income | -217.2M | ↓ 688.49% |
Net Profit Margin | -94.64% | ↓ 106.48% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 106.3M | ↓ 53.69% |
Net Income | -28.1M | ↓ 87.04% |
Net Profit Margin | -26.48% | ↑ 68.16% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 111.0M | ↑ 4.46% |
Net Income | -1.3M | ↓ 95.45% |
Net Profit Margin | -1.15% | ↑ 25.33% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 156.2M | ↑ 40.73% |
Net Income | 109.6M | ↓ 8657.77% |
Net Profit Margin | 70.17% | ↑ 71.32% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 33.3M | ↑ 30.84% |
Net Income | 4.6M | ↑ 23.25% |
Net Profit Margin | 13.82% | ↓ 0.85% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 36.5M | ↑ 9.63% |
Net Income | 9.1M | ↑ 96.79% |
Net Profit Margin | 24.81% | ↑ 10.99% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 35.1M | ↓ 3.85% |
Net Income | 7.8M | ↓ 13.57% |
Net Profit Margin | 22.3% | ↓ 2.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 34.2M | ↓ 2.62% |
Net Income | 4.2M | ↓ 46.72% |
Net Profit Margin | 12.2% | ↓ 10.1% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 50.4M | ↑ 47.18% |
Net Income | 88.6M | ↑ 2021.49% |
Net Profit Margin | 175.86% | ↑ 163.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 42.5M | ↓ 15.66% |
Net Income | -3.5M | ↓ 103.93% |
Net Profit Margin | -8.2% | ↓ 184.06% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↓ 15.24% |
Total Liabilities | 869.1M | ↓ 10.82% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 932.9M | ↓ 10.18% |
Total Liabilities | 712.5M | ↓ 18.02% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 527.2M | ↓ 43.49% |
Total Liabilities | 469.2M | ↓ 34.15% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 303.3M | ↓ 42.47% |
Total Liabilities | 247.8M | ↓ 47.2% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 326.5M | ↑ 7.67% |
Total Liabilities | 224.1M | ↓ 9.54% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 413.9M | ↑ 26.75% |
Total Liabilities | 188.2M | ↓ 16.04% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 326.5M | ↑ 9.1% |
Total Liabilities | 224.1M | ↑ 10.71% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 339.1M | ↑ 3.85% |
Total Liabilities | 227.3M | ↑ 1.4% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 322.0M | ↓ 5.06% |
Total Liabilities | 193.6M | ↓ 14.81% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 323.3M | ↑ 0.42% |
Total Liabilities | 188.4M | ↓ 2.67% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 413.9M | ↑ 28.01% |
Total Liabilities | 188.2M | ↓ 0.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 414.3M | ↑ 0.09% |
Total Liabilities | 163.6M | ↓ 13.06% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 62.2M | ↓ 5.09% |
Investing Cash Flow | 57.9M | ↑ 27.14% |
Financing Cash Flow | -110.9M | ↑ 17.45% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 72.5M | ↑ 16.62% |
Investing Cash Flow | -7.1M | ↓ 112.23% |
Financing Cash Flow | -81.4M | ↓ 26.64% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 90.5M | ↑ 24.8% |
Investing Cash Flow | -1.5M | ↓ 79.09% |
Financing Cash Flow | -157.8M | ↑ 94.02% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -65.6M | ↓ 172.48% |
Investing Cash Flow | 512.8M | ↓ 34725.32% |
Financing Cash Flow | -468.6M | ↑ 196.86% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.5M | ↓ 108.42% |
Investing Cash Flow | -18.5M | ↓ 103.61% |
Financing Cash Flow | 29.0M | ↓ 106.19% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.1M | ↓ 11.24% |
Investing Cash Flow | -18.5M | ↑ 0.0% |
Financing Cash Flow | -7.5M | ↑ 2012.92% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.4M | ↑ 563.91% |
Investing Cash Flow | -404.0K | ↓ 97.82% |
Financing Cash Flow | -2.4M | ↓ 67.52% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 14.4M | ↓ 47.39% |
Investing Cash Flow | -16.1M | ↑ 3888.61% |
Financing Cash Flow | -7.4M | ↑ 204.58% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 10.0M | ↓ 30.39% |
Investing Cash Flow | -371.0K | ↓ 97.7% |
Financing Cash Flow | 2.9M | ↓ 138.81% |
Sell
Neutral
Buy
Assertio Holdings, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Assertio Holdings, Inc. | 10.09% | 111.0% | 104.85% | 58.25% | -80.32% |
![]() Neurocrine Biosciences Inc. | -13.93% | -29.12% | -3.47% | -27.45% | -9.1% |
![]() Zoetis Inc. | -9.22% | 4.07% | -2.4% | 17.83% | 90.83% |
![]() Viatris Inc. | -2.24% | -18.59% | -24.19% | -44.0% | -44.0% |
![]() Catalent, Inc. | -25.72% | -28.72% | -64.37% | -51.42% | -6.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Assertio Holdings, Inc. | 3.69 | 3.69 | 0.62 | 0.37 | 0.54 | 0.1 | 0.0 | 4.5 |
![]() Neurocrine Biosciences Inc. | 145.34 | 145.34 | 1.87 | 2.1 | 0.04 | 0.08 | 0.0 | 17.28 |
![]() Zoetis Inc. | 36.41 | 36.41 | 3.53 | 5.4 | 0.45 | 0.13 | 0.01 | 9.72 |
![]() Viatris Inc. | 5.8 | 5.8 | NA | 2.95 | 0.09 | 0.03 | 0.05 | 17.45 |
![]() Catalent, Inc. | 15.88 | 15.88 | 1.18 | 1.37 | 0.09 | 0.04 | 0.0 | 27.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Assertio Holdings, Inc. | Buy | $359.6M | -80.32% | 3.69 | 59.86% |
![]() Neurocrine Biosciences Inc. | Buy | $8.8B | -9.1% | 145.34 | 4.0% |
![]() Zoetis Inc. | Buy | $74.4B | 90.83% | 36.41 | 25.59% |
![]() Viatris Inc. | Hold | $10.9B | -44.0% | 5.8 | 12.05% |
![]() Catalent, Inc. | Buy | $6.5B | -6.08% | 15.88 | 8.62% |
Vanguard Group Inc
Renaissance Technologies Corp
Acadian Asset Management LLC
LITTLEJOHN & CO LLC
Millennium Management LLC
BlackRock Inc
Organization | Assertio Holdings, Inc. |
Employees | 30 |
CEO | Mr. Daniel A. Peisert |
Industry | Health Technology |